• 1
    Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part 1: short-term prognosis. Gut 1963; 4: 3008.
  • 2
    Stenson WF. Inflammatory bowel disease. In: YamadaTed. Textbook of Gastroenterology: A Community Study, 2nd ed. Philadelphia: JB Lippincott Company, 1995: 1748806
  • 3
    Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 106770.
  • 4
    Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 100513.
  • 5
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 90510.
  • 6
    Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 2739.
  • 7
    Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 107987.
  • 8
    Cohen RD, Brodsky AL, Hannauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 5: 110.
  • 9
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclopsporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 184151.
  • 10
    Carbonnel F, Boruchowitz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 24716.
  • 11
    Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 738.
  • 12
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 13
    Järnerot G, Hertevig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized placebo-controlled study. Gastroenteroloy 2005; 128: 180511.
  • 14
    Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001; 96: 237381.
    Direct Link:
  • 15
    Kohn A, Prantera C, Pera A, et al. Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2003; 34: 62630.
  • 16
    Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid-refractory ulcerative colitis (a pilot study). Wien Klin Wochenschr 2001; 113: 9303.
  • 17
    Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflammatory Bowel Dis 2005; 11: 2138.
  • 18
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 838.
  • 19
    Kohn A, Prantera C, Pera A, et al. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 2004; 8: 2357.
  • 20
    Prantera C, Lorenzetti R, Cerro P, et al. The plain abdominal film accurately estimates extent of active ulcerative colitis. J Clin Gastroenterol 1991; 13: 2314.
  • 21
    Carbonnel F, Lavergne A, Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 15507.
  • 22
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 10418.
  • 23
    Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Gut 1986; 27: 12102.
  • 24
    Lichtiger S, Present D. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 169.
  • 25
    Bland M. An Introduction to Medical Statistics, 3rd edn . Oxford, UK: Oxford University Press, 2000.
  • 26
    Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19: 74954.
  • 27
    Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 95662.
  • 28
    Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires’ disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154: 241722.
  • 29
    Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337: 6827.
  • 30
    Li Gobbi F, Benucci M, Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 2005; 11: 11920.
  • 31
    Wondergem MJ, Voskuyl AE, Van Agtmael MA. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 2004; 36: 3101.
  • 32
    Albert C, Vandebos F, Brocq O, et al. Legionellosis in patient treated with infliximab. Rev Med Interne 2004; 25: 1678.
  • 33
    Eisendle K, Fritsch P. Fatal fulminant legionnaires’ disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy. Br J Dermatol 2005; 152: 5856.
  • 34
    McHugh SL, Newton CA, Yamamoto Y, et al. Tumour necrosis factor induces resistance of macrophages to Legionella pneumophila infection. Proc Soc Exp Biol Med 2000; 124: 1916.
  • 35
    Skerrett SJ, Bagby GJ, Schmidt RA, et al. Antibody-mediated depletion of tumour necrosis factor-a impairs pulmonary host defences to Legionella pneumophila. J Infect Dis 1997; 176: 101928.
  • 36
    Shibolet O, Requshevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1: CD004277.
  • 37
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterology 1999; 94: 158792.
    Direct Link:
  • 38
    Alves A, Panis Y, Bounhik Y, et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003; 197: 37985.
  • 39
    Seelig MH, Uhlig H, Braun J, et al. Surgical therapy of severe colitis. Chirug 1996; 67: 15054s.
  • 40
    Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg 2003; 186: 5148.
  • 41
    Jacobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull 2006; 76: 13144.
  • 42
    Hahnloser D, Pemberton JH, Wolff BG, et al. The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis. Ann Surg 2004; 240: 61521.